Andrew Goodman

14.9k total citations · 2 hit papers
149 papers, 7.8k citations indexed

About

Andrew Goodman is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Andrew Goodman has authored 149 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pathology and Forensic Medicine, 31 papers in Neurology and 22 papers in Rheumatology. Recurrent topics in Andrew Goodman's work include Multiple Sclerosis Research Studies (79 papers), Peripheral Neuropathies and Disorders (22 papers) and Polyomavirus and related diseases (15 papers). Andrew Goodman is often cited by papers focused on Multiple Sclerosis Research Studies (79 papers), Peripheral Neuropathies and Disorders (22 papers) and Polyomavirus and related diseases (15 papers). Andrew Goodman collaborates with scholars based in United States, Switzerland and Canada. Andrew Goodman's co-authors include Michael McDermott, Samuel Ralph Powers, Alton L. Steiner, S. R. Schwid, Andrew R. Blight, Lauren Krupp, Ron Cohen, Lawrence N. Marinucci, Randall T. Schapiro and Steven R. Schwid and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Andrew Goodman

143 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

STUDY OF A KINDRED WITH PHEOCHROMOCYTOMA, MEDULLARY THYROID CARCINOMA, HYPERPARATHYROIDISM AND GUSHING ʼS DISEASE: MULTIPLE ENDOCRINE NEOPLASIA, TYPE 21

1968 460 citations Andrew Goodman et al. profile →
Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta.

1985 364 citations Andrew Goodman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Goodman United States	49	4.3k	1.9k	1.3k	1.1k	937	149	7.8k
Joseph Herbert United States	50	2.7k 0.6×	1.2k 0.6×	2.1k 1.6×	381 0.3×	683 0.7×	116	7.9k
Anat Achiron Israel	51	4.3k 1.0×	2.0k 1.1×	1.1k 0.8×	687 0.6×	850 0.9×	320	8.6k
Maria Giovanna Marrosu Italy	45	3.0k 0.7×	1.5k 0.8×	1.5k 1.2×	658 0.6×	867 0.9×	248	6.7k
Mohammad Ali Sahraian Iran	42	4.5k 1.0×	1.5k 0.8×	1.1k 0.9×	752 0.7×	1.0k 1.1×	447	7.5k
Dennis Bourdette United States	56	3.7k 0.9×	1.5k 0.8×	1.6k 1.3×	737 0.6×	845 0.9×	251	9.2k
Anthony T. Reder United States	48	4.4k 1.0×	1.6k 0.8×	1.5k 1.2×	1.3k 1.1×	1.3k 1.4×	160	7.3k
Alireza Minagar United States	43	2.3k 0.5×	1.4k 0.7×	1.8k 1.4×	648 0.6×	877 0.9×	261	7.3k
Rohit Bakshi United States	67	9.2k 2.1×	3.8k 2.0×	2.0k 1.6×	784 0.7×	2.1k 2.3×	259	14.2k
Robert P. Lisak United States	55	4.8k 1.1×	4.5k 2.4×	2.0k 1.6×	1.4k 1.2×	1.5k 1.6×	304	11.9k
Nicholas J. Patronas United States	46	1.1k 0.3×	1.1k 0.6×	1.2k 0.9×	566 0.5×	473 0.5×	106	7.3k

Countries citing papers authored by Andrew Goodman

Since Specialization

Citations

This map shows the geographic impact of Andrew Goodman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Goodman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Goodman more than expected).

Fields of papers citing papers by Andrew Goodman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Goodman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Goodman. The network helps show where Andrew Goodman may publish in the future.

Co-authorship network of co-authors of Andrew Goodman

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Goodman. A scholar is included among the top collaborators of Andrew Goodman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Goodman. Andrew Goodman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jakimovski, Dejan, Katelyn Kavak, Patricia K. Coyle, et al.. (2023). Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium. Journal of Neurology. 271(2). 711–722. 5 indexed citations

Cohen, Jeffrey A., Michelle Cameron, Myla Goldman, et al.. (2021). A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal. 28(5). 817–830. 3 indexed citations

Hyland, Megan, et al.. (2019). Comparison of telemedicine versus in-person visits for persons with multiple sclerosis: A randomized crossover study of feasibility, cost, and satisfaction. Multiple Sclerosis and Related Disorders. 36. 101258–101258. 69 indexed citations

Fox, Robert J., Matthew Karafa, Christian Barro, et al.. (2019). Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial (P3.2-033). Neurology. 92(15_supplement). 4 indexed citations

Duffy, Charles J., et al.. (2018). Novel computer-based testing shows multi-domain cognitive dysfunction in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 4(2). 2453187426–2453187426. 7 indexed citations

Fox, Robert J., Christopher S. Coffey, Merit Cudkowicz, et al.. (2015). NN 102/SPRINT-MS Phase II Trial of Ibudilast in Progressive MS: Baseline Characteristics (P7.214). Neurology. 84(14_supplement). 1 indexed citations

Kavak, Katelyn, Barbara Teter, Jesper Hagemeier, et al.. (2014). Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Multiple Sclerosis Journal. 21(7). 858–865. 41 indexed citations

Goodman, Andrew, et al.. (2014). A Pooled Analysis of Two Phase 3 Clinical Trials of Dalfampridine in Patients with Multiple Sclerosis. International Journal of MS Care. 16(3). 153–160. 24 indexed citations

Hobart, Jeremy, Andrew R. Blight, Andrew Goodman, Frances Lynn, & Norman Putzki. (2013). Timed 25-Foot Walk. Neurology. 80(16). 1509–1517. 138 indexed citations

10.

Applebee, Angela, Andrew Goodman, François Béthoux, et al.. (2013). Effects of 5mg and 10mg Dalfampridine Extended Release Tablets on 6-Minute Walk Distance in People with Multiple Sclerosis: A Subgroup Analysis of a Double-Blind, Placebo-Controlled Trial (S01.007). Neurology. 80(7_supplement). 1 indexed citations

11.

Goodman, Andrew, Theodore R. Brown, Keith R. Edwards, et al.. (2010). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology. 68(4). 494–502. 246 indexed citations

12.

Ito, Masumi, Benjamin M. Blumberg, David J. Mock, et al.. (2001). Potential Environmental and Host Participants in the Early White Matter Lesion of Adreno-Leukodystrophy: Morphologic Evidence for CD8 Cytotoxic T Cells, Cytolysis of Oligodendrocytes, and CD1-Mediated Lipid Antigen Presentation. Journal of Neuropathology & Experimental Neurology. 60(10). 1004–1019. 89 indexed citations

13.

Johnson, K. P., Benjamin Brooks, Corey C. Ford, et al.. (2000). Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis Journal. 6(4). 255–266. 170 indexed citations

14.

Schwid, S. R., Andrew Goodman, Brian R. Apatoff, et al.. (2000). Are quantitative functional measures more sensitive to worsening MS than traditional measures?. Neurology. 55(12). 1901–1903. 29 indexed citations

15.

Blumberg, Benjamin M., David J. Mock, James M. Powers, et al.. (2000). The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. Journal of Clinical Virology. 16(3). 159–178. 63 indexed citations

16.

Mock, David J., James M. Powers, Andrew Goodman, et al.. (1999). Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy. Journal of NeuroVirology. 5(4). 363–373. 37 indexed citations

17.

Carroll, Patricia B., Raymonde D Herskowitz, Andrew Goodman, Robert S. Busch, & Richard S. Beaser. (1992). Rapid onset of severe retinopathy, cataracts and neuropathy in young patients with diabetes mellitus. Acta Paediatrica. 81(4). 355–358. 7 indexed citations

18.

Goodman, Andrew. (1992). Empathy and Inquiry. Contemporary Psychoanalysis. 28(4). 631–646. 2 indexed citations

19.

Goodman, Andrew, et al.. (1988). Effects of Prolactin and Growth Hormone on Tissue and Serum Carnitine in the Rat*. Endocrinology. 123(4). 1955–1961. 3 indexed citations

20.

Goodman, Andrew, et al.. (1985). Rubella outbreak among office workers--New York City. MMWR Morbidity and Mortality Weekly Report. 34(29). 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact